Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India's FIPB clears Daiichi Sankyo's deal with Ranbaxy

This article was originally published in Scrip

Executive Summary

India's Foreign Investment Promotion Board (FIPB) has approved Daiichi Sankyo's acquisition ofRanbaxy Laboratories, which entails a foreign direct investment (FDI) inflow of Rs215.6 billion ($4.9 billion) but recommended that the proposal be considered by India’s cabinet committee on economic affairs (CCEA). Indian regulations require all proposals with FDI exceeding Rs6 billion to be submitted for cabinet approval. The FIPB approved the deal on July 29th, but had to re-calculate the amount of FDI from the acquisition and hence reconsider the proposal, local media reports said. Daiichi Sankyo signed a share purchase agreement with Ranbaxy's founding family to acquire 34.81% of the company’s equity capital at Rs737 ($17.18) per share. It followed this up with an offer to the remaining shareholders of Ranbaxy Laboratories to acquire up to 92,519,126 equity shares of Rs5 each, representing 20% of the Indian company’s voting capital, at Rs737 per share. The offer closes on September 4th.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts